Unicycive's phosphate binder gets March 2027 FDA review target after manufacturer switch
The US regulator has taken up the refiled oxylanthanum carbonate application, which now names a new manufacturer, leaving the small-cap company with a dated path to a possible launch.
Unicycive Therapeutics now has a date on which its dialysis drug could win US approval: 25 March 2027. That is the target the FDA has set for its review of the refiled application for oxylanthanum carbonate, a phosphate binder for hyperphosphatemia in patients on dialysis. The company disclosed the acceptance with its third-quarter 2026 results.
Subscribe to keep reading
$4.99 / month
- Every article, analysis and opinion piece on CompePharma and VigiEye
- One subscription for both sites, cancel any time
Already a subscriber? Enter your email below: we'll send you a sign-in link. No password needed.
Company's press release (SEC filing): Unicycive Therapeutics, Inc. ↗
Written by CompePharma's editorial system from the company's filing; claims are the company's. AI-assisted; check the source before acting. Not investment advice.